We target the cells
that drive fibrosis
Activated myofibroblasts play a pivotal role in fibrosis. To reach these cells, we designed Fibrobodies®. These proprietary and first-in-class proteins bind selectively to activated myofibroblasts in fibrotic tissue.
Fibrobodies® can be equipped with virtually any ‘payload’, unlocking various possibilities to diagnose and treat fibrosis.
Research points to long-term growth in a multitude of fibrotic illnesses.
In the US alone, almost five million people are living with chronic liver disease
Kidney fibrosis affects as many as 50 million people in the EU and USA alone
Other than transplant or the removal of the affected organs, there are no curative treatment options for advanced fibrosis
UK deaths due to liver disease have risen by 400% since 1970 (britishlivertrust.org.uk)
Modern Western lifestyle will cause a rise of fibrotic disease within years
Lung fibrosis may develop in more than half of severe COVID-19 patients
Our team of dedicated scientists have broad experience in targeted drug delivery. Within the Amsterdam UMC Imaging Center, we have access to state-of-the-art facilities including radioactive tracer production facilities, chemical and biochemical laboratories, preclinical facilities, and preclinical- and clinical Imaging equipment (PET/CT, PET/MRI).
1081 GM Amsterdam